Beyond the scale: what medical weight loss can change

Hunger and satiety are regulated through hormones, the gastrointestinal tract and the brain. When weight is lost, the body can respond with stronger hunger signals and lower energy expenditure, making maintenance difficult for some people.

This matters because of how it changes the interpretation of past attempts. Someone who has lost weight repeatedly and regained it has not demonstrated a character flaw; they have demonstrated a physiological response that is well described in the literature. Understanding that is not an excuse, but it does remove a layer of shame that frequently stops people seeking help at all.

Contributors worth identifying before treatment

• Untreated sleep apnoea, which affects both weight and cardiovascular risk.
• Thyroid disease and other endocrine conditions.
• Medications that promote weight gain, including some antidepressants, antipsychotics, steroids and beta-blockers.
• Chronic sleep restriction, which alters appetite hormones directly.
• Polycystic ovary syndrome and insulin resistance.

GLP-1 receptor agonists influence appetite and satiety and can improve glucose regulation. Some products are approved for chronic weight management, while others are approved for diabetes. The exact indication and dose depend on the specific product.

Medication is one option rather than the only one, and it is not the right starting point for everyone. For a detailed comparison of the tablet and injectable formats, see our article on oral GLP-1 medicines versus injections.

For appropriate patients, clinically meaningful weight reduction can be associated with improvements in blood pressure, glycaemic control, mobility and several weight-related health risks. Cardiovascular-outcomes research has also changed how clinicians think about selected GLP-1 therapies in higher-risk patients.

The proportion matters more than the absolute figure. Research consistently finds that a reduction of around 5–10% of starting body weight produces measurable metabolic benefit — improvements in blood pressure, glucose control and lipids — which is far less than most people set as their personal target. Someone weighing 90kg who loses 7kg has achieved something clinically significant, even though it may not look like the transformation they imagined.

These effects are not guaranteed for every person, and medication does not replace attention to nutrition, physical activity, sleep and other health conditions.

Body weight fluctuates by a kilogram or more day to day through fluid, food volume, salt intake and hormonal cycles. Daily weighing therefore produces a noisy signal that can be discouraging for reasons that have nothing to do with fat.

Common adverse effects of GLP-1 medicines are gastrointestinal and may include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. Suitability also depends on medical history, current medicines and the exact drug being considered.

Rapid weight reduction can also reduce lean mass if protein intake and resistance exercise are neglected. A good programme therefore considers body composition and function, not just weight.

Protecting muscle during weight loss

Adequate protein and resistance training are the two measures that determine how much of the loss is fat rather than lean tissue. This becomes more important with age, since muscle is harder to rebuild later, and it is the single most commonly neglected part of a weight programme.

Weight loss is rarely linear. Plateaus are expected, partly because a lighter body requires less energy and partly because the physiological adaptations described earlier become more pronounced as loss continues. A plateau is a normal stage rather than evidence that something has stopped working.

Setbacks behave the same way. A difficult few weeks does not undo prior progress, and the pattern of abandoning a plan after a lapse causes more harm than the lapse itself. The clinically useful response is to resume, not to restart from zero with a stricter version of the same approach.

Where progress genuinely stalls for an extended period, that is a reason for review — of medication dose, of contributing conditions, of protein and activity — rather than for simply eating less.

Weight-management medicines can be powerful tools, but the clinical goal is a sustainable strategy. Follow-up should address dose, side effects, nutrition, physical activity, sleep, weight maintenance and what happens if medication is reduced or stopped.

That last point deserves planning at the start rather than the end. Weight regain after stopping is a well-documented physiological response, so a treatment decision should include some thought about the years after, not only the months during.

Related services: health screening to identify contributing conditions, chronic disease management for blood pressure, glucose and cholesterol, and sleep apnoea assessment, which is frequently the missed factor in weight that will not shift.

Weighing up tablets against injections? Our guide to oral GLP-1 medicines compares the two.